000 01197 a2200337 4500
005 20250513132950.0
264 0 _c19980305
008 199803s 0 0 eng d
022 _a1040-8401
024 7 _a10.1615/critrevimmunol.v18.i1-2.120
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSalgaller, M L
245 0 0 _aDendritic cell-based immunotherapy of prostate cancer.
_h[electronic resource]
260 _bCritical reviews in immunology
_c1998
300 _a109-19 p.
_bdigital
500 _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aDendritic Cells
_xcytology
650 0 4 _aHumans
650 0 4 _aImmunotherapy
650 0 4 _aMale
650 0 4 _aProstate-Specific Antigen
_ximmunology
650 0 4 _aProstatic Neoplasms
_xtherapy
700 1 _aTjoa, B A
700 1 _aLodge, P A
700 1 _aRagde, H
700 1 _aKenny, G
700 1 _aBoynton, A
700 1 _aMurphy, G P
773 0 _tCritical reviews in immunology
_gvol. 18
_gno. 1-2
_gp. 109-19
856 4 0 _uhttps://doi.org/10.1615/critrevimmunol.v18.i1-2.120
_zAvailable from publisher's website
999 _c9389025
_d9389025